In conclusion, this systematic review and network meta-analysis comprehensively summarized and analyzed current available evidence of the second-line treatments, evaluated in RCTs, for trastuzumab-treated, HER2-positive, advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.